Voyager CEO Al Sandrock outlines a focused strategy: remain specialists in neurology, but broaden the therapeutic modalities (gene therapy, proteins, oligonucleotides). This allows them to pursue well-validated CNS targets that are considered "undruggable" by traditional small molecules, which have historically been the only option for crossing the blood-brain barrier.

To build investor confidence in the high-risk neuroscience field, Neurocrine employs a dual strategy. It highlights its own proven track record while simultaneously de-risking its pipeline by targeting biological pathways already validated by competitors, aiming to create superior, best-in-class medicines rather than pursuing unproven science.

In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.

Leal's work shows the link between the brain and metabolism is bidirectional. While developing drugs for CNS disorders, they discovered that engaging metabolic targets within the CNS can produce powerful peripheral effects, like selective fat loss, creating unexpected therapeutic opportunities in massive markets like obesity.

Facing industry-wide skepticism in 2010, Alnylam implemented a highly disciplined R&D strategy. They focused exclusively on targets that met strict criteria: liver expression (where delivery worked), human genetic validation (to de-risk biology), and an early biomarker. This strategic focus was key to their survival and success.

The company's R&D strategy pragmatically filters for targets that are not only highly validated and accessible with its current technology, but are also already on the radar of potential big pharma partners ("strategics"), indicating a clear market and potential exit path.

Instead of targeting complex downstream glutamate receptors, Leal Therapeutics inhibits a single upstream enzyme, glutaminase. This mechanistically simpler approach avoids the off-target effects of receptor-based drugs and allows for direct, quantifiable measurement of target engagement, a major advantage in CNS trials.

Leal Therapeutics intentionally built a team capable of developing both oral small molecules and nucleic acid drugs. This dual-modality platform provides strategic agility, allowing them to select the optimal therapeutic approach for a given disease, such as an intrathecal ASO for ALS and a brain-penetrant small molecule for broader indications.

Step Pharma's confidence in their drug's clean safety profile originated from studying a human population with a natural mutation in the CTPS1 gene. This real-world genetic data de-risked their therapeutic approach from the outset, guiding development towards a highly selective and safe inhibitor.